Daewoong Pharmaceutical (India) Profile
Key Indicators
- Authorised Capital ₹ 2.90 Cr
as on 24-10-2024
- Paid Up Capital ₹ 2.86 Cr
as on 24-10-2024
- Company Age 12 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 3.07%
(FY 2023)
- Profit -22.52%
(FY 2023)
- Ebitda 59.37%
(FY 2023)
- Net Worth 10.49%
(FY 2023)
- Total Assets 159.39%
(FY 2023)
About Daewoong Pharmaceutical (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.90 Cr and a paid-up capital of Rs 2.86 Cr, as per Ministry of Corporate Affairs (MCA) records.
Chung Song, Gwan Kim, and Neelima Aryasomayajula serve as directors at the Company.
- CIN/LLPIN
U24232TG2012FTC084511
- Company No.
084511
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
30 Nov 2012
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Daewoong Pharmaceutical (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chung Song  | Director | 08-Feb-2016 | Current |
| Gwan Kim | Director | 09-Apr-2018 | Current |
Neelima Aryasomayajula  | Additional Director | 23-May-2024 | Current |
Financial Performance of Daewoong Pharmaceutical (India).
Daewoong Pharmaceutical (India) Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.07% increase. The company also saw a substantial fall in profitability, with a 22.52% decrease in profit. The company's net worth Soared by an impressive increase of 10.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Daewoong Pharmaceutical (India)?
In 2023, Daewoong Pharmaceutical (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Daewoong Pharmaceutical (India)?
Daewoong Pharmaceutical (India) has a workforce of 23 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Daewoong Pharmaceutical (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Daewoong Pharmaceutical (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
